[{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2025-02-25T12:26:32.593Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2025-02-24"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"2223e62c-2304-4f09-b793-71e2fb24f5a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03224767","created_at":"2021-04-28T13:53:13.407Z","updated_at":"2025-02-25T14:15:02.976Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma","source_id_and_acronym":"NCT03224767","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-18"},{"id":"ab1e1b4a-5cc0-492c-9676-f254993a91a1","acronym":"ETCTN Study 10166","url":"https://clinicaltrials.gov/study/NCT03600701","created_at":"2021-01-18T17:42:08.981Z","updated_at":"2025-02-25T14:15:13.480Z","phase":"Phase 2","brief_title":"Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03600701 - ETCTN Study 10166","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • KRAS • BRAF • ALK","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2025","study_completion_date":" 07/17/2025","last_update_posted":"2025-02-17"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"6d9c9dc1-5735-46b5-bfc4-9aa69eeeef0c","acronym":"BFAST","url":"https://clinicaltrials.gov/study/NCT03178552","created_at":"2021-01-18T15:40:25.224Z","updated_at":"2025-02-25T15:17:28.532Z","phase":"Phase 2/3","brief_title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03178552 - BFAST","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • TMB","pipe":"","alterations":" ","tags":["BRAF • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 08/03/2028","primary_completion_date":" 08/03/2028","study_txt":" Completion: 08/03/2028","study_completion_date":" 08/03/2028","last_update_posted":"2025-02-12"},{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"f3c62253-8046-49b1-bb25-cd529c350b91","acronym":"MORPHEUS-PDAC","url":"https://clinicaltrials.gov/study/NCT03193190","created_at":"2021-01-18T15:44:27.682Z","updated_at":"2025-02-25T16:36:54.744Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","source_id_and_acronym":"NCT03193190 - MORPHEUS-PDAC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-02-06"},{"id":"577a4268-ea8b-44ef-b557-7019f2e329c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691504","created_at":"2023-01-20T16:00:14.081Z","updated_at":"2025-02-25T16:46:30.558Z","phase":"Phase 1","brief_title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","source_id_and_acronym":"NCT05691504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • BCL2L1","pipe":"","alterations":" ","tags":["BRAF • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-05"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"75f0b64e-2f38-4d3f-986a-4f0367fd8684","acronym":"BOUQUET","url":"https://clinicaltrials.gov/study/NCT04931342","created_at":"2022-05-03T17:53:37.321Z","updated_at":"2024-07-02T16:34:26.433Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","source_id_and_acronym":"NCT04931342 - BOUQUET","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/07/2021","start_date":" 10/07/2021","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"f89835c0-06e4-4e0a-885b-6ba816427d90","acronym":"","url":"https://clinicaltrials.gov/study/NCT03202316","created_at":"2021-01-18T15:47:27.316Z","updated_at":"2024-07-02T16:34:59.898Z","phase":"Phase 2","brief_title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","source_id_and_acronym":"NCT03202316","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/11/2017","start_date":" 08/11/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-31"},{"id":"2a264a2b-5ea5-4bd0-8407-7b2b5f234d25","acronym":"NACHO COBI","url":"https://clinicaltrials.gov/study/NCT04079179","created_at":"2021-01-18T19:58:29.856Z","updated_at":"2024-07-02T16:35:00.684Z","phase":"Phase 2","brief_title":"Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders","source_id_and_acronym":"NCT04079179 - NACHO COBI","lead_sponsor":"Carl Allen","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/19/2021","start_date":" 04/19/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-27"},{"id":"66295375-7bb9-499f-9a29-4931cfd6243c","acronym":"NeoACTIVATE","url":"https://clinicaltrials.gov/study/NCT03554083","created_at":"2021-01-18T17:29:17.667Z","updated_at":"2024-07-02T16:35:01.056Z","phase":"Phase 2","brief_title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","source_id_and_acronym":"NCT03554083 - NeoACTIVATE","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2018","start_date":" 10/05/2018","primary_txt":" Primary completion: 06/29/2025","primary_completion_date":" 06/29/2025","study_txt":" Completion: 06/29/2025","study_completion_date":" 06/29/2025","last_update_posted":"2024-05-24"},{"id":"b30b1e44-f866-4d50-98ee-25a4b13b78d0","acronym":"ImmunoCobiVem","url":"https://clinicaltrials.gov/study/NCT02902029","created_at":"2021-03-22T16:53:54.040Z","updated_at":"2024-07-02T16:35:01.852Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","source_id_and_acronym":"NCT02902029 - ImmunoCobiVem","lead_sponsor":"University Hospital, Essen","biomarkers":" PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-05-23"},{"id":"c6296d46-2509-4857-a66a-8bdd1dea5322","acronym":"BEAT-MBM","url":"https://clinicaltrials.gov/study/NCT03175432","created_at":"2021-01-18T15:39:32.617Z","updated_at":"2024-07-02T16:35:02.815Z","phase":"Phase 2","brief_title":"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases","source_id_and_acronym":"NCT03175432 - BEAT-MBM","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/15/2017","start_date":" 06/15/2017","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-17"},{"id":"37f9a1df-a306-4aaa-b1f0-111ca2107f32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04835805","created_at":"2021-04-08T13:52:36.101Z","updated_at":"2024-07-02T16:35:03.372Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.","source_id_and_acronym":"NCT04835805","lead_sponsor":"Genentech, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/13/2021","start_date":" 05/13/2021","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 11/28/2025","study_completion_date":" 11/28/2025","last_update_posted":"2024-05-16"},{"id":"d2b7a6bc-a50d-43d6-9188-90e486052fd6","acronym":"CheckMate142","url":"https://clinicaltrials.gov/study/NCT02060188","created_at":"2021-01-17T17:13:48.793Z","updated_at":"2024-07-02T16:35:04.397Z","phase":"Phase 2","brief_title":"A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread","source_id_and_acronym":"NCT02060188 - CheckMate142","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Darzalex (daratumumab) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 385","initiation":"Initiation: 03/12/2014","start_date":" 03/12/2014","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-05-10"},{"id":"a78b33a3-01e4-47a2-a800-be3b90f90ba4","acronym":"MODUL","url":"https://clinicaltrials.gov/study/NCT02291289","created_at":"2021-01-18T10:48:03.897Z","updated_at":"2025-02-25T14:00:31.914Z","phase":"Phase 2","brief_title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT02291289 - MODUL","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Perjeta (pertuzumab) • Cotellic (cobimetinib) • capecitabine • oxaliplatin • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 1044","initiation":"Initiation: 04/17/2015","start_date":" 04/17/2015","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 03/24/2021","study_completion_date":" 03/24/2021","last_update_posted":"2024-05-06"}]